The FDA’s accelerated approval of elranatamab offers a new therapeutic pathway for adults with relapsed or refractory multiple myeloma. With promising response rates and an established safety profile, this treatment may provide a much-needed option for those struggling with relapsed myeloma.

The ASCO 2023 meeting has unveiled key studies in prostate cancer, including insights into PSA levels post-radiation therapy, the role of BRCA mutations, and promising combination therapies.

Explore the latest Medscape Wealth and Debt report to understand the financial trends among physicians, including the top earning specialties and the influence of gender and race on net worth. Gain insights into what motivates your peers in this comprehensive analysis.

This prospective cohort study presents compelling evidence that omitting radiotherapy in women over 55 with specific luminal A breast cancer characteristics may lead to a low incidence of local recurrence at 5 years.

The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.

Explore the insights of a family physician who tested ChatGPT’s understanding of a typical day in medical practice. Discover where the AI excels and where it falls short, particularly in areas like billing and time management.